The company will not receive any proceeds from the resale or other disposition of the shares of common stock by the selling securityholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla reports Q1 EPS (26c), consensus (29c)
- BioAtla announces poster presentations at 2025 AACR meeting
- BioAtla price target lowered to $1 from $5 at Citizens JMP
- BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
- Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside